IRIS: Infection with RespIratory Syncytial Virus in infants—a prospective observational cohort study

Abstract

Background Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection in infants. Globally, RSV is responsible for approximately 3.2 million hospital admissions and about 60,000 in-hospital deaths per year. Methods Infection with RespIratory Syncytial Virus (IRIS) is an observational, multi-centre study enrolling infants with severe RSV infection and healthy controls. Inclusion criteria are age between 0 and 36 months and hospitalisation due to RSV infection at three German sites. Exclusion criteria are premature birth, congenital or acquired bronchopulmonary or cardiac diseases, and immunodeficiency. Healthy control probands are enrolled via recruitment of patients undergoing routine surgical procedures. Blood and respiratory specimens are collected upon admission, and RSV and other pathogens are analysed by multiplex polymerase chain reaction. Different biomaterials, including plasma, nasal lining fluid, blood cells, DNA, and RNA specimens, are sampled in a dedicated biobank. Detailed information on demographic characteristics and medical history is recorded, and comprehensive clinical data, including vital signs, medication, and interventions. Discussion The IRIS study aims to discover host and viral factors controlling RSV disease courses in infants. The approach including multi-omics characterisation in clinically well-characterized children with RSV bronchiolitis seeks to improve our understanding of the immune response against this virus. It may disclose novel diagnostic and treatment approaches for respiratory infections in infants. Trial registration: ClinicalTrials.gov, NCT04925310. Registered 01 October 2021—Retrospectively registered. https://clinicaltrials.gov/ct2/show/NCT04925310?cond=NCT04925310&draw=2&rank=1

A relation between specific immune status indicators and activity of “lipid peroxidation — antioxidant defense” system in COVID-19 neonates

“…Есть разные предположения относительно данного факта, среди них -наличие у детей более активного врожденного иммунного ответа, более здоровых дыхательных путей, более «энергичного» иммунного ответа у взрослых [20,22,27]. Одновременное присутствие других вирусов в слизистой оболочке легких и дыхательных путей, которые часто встречаются у детей раннего возраста, может ограничить рост SARS-CoV-2 путем прямого вирус-вирусного взаимодействия и конкуренции [34]. Известно также, что дети менее подвержены воздействию новой коронавирусной инфекции по причине незрелости системы иммунитета [23].…”

Viral Airway Injury Promotes Cell Engraftment in anIn VitroModel of Cystic Fibrosis Cell Therapy

“…The concept of delivering cells primed for viral resistance to infected airways has therapeutic potential beyond CF. Globally, severe viral infection represents a major health burden with ~60,000 deaths per year caused by respiratory syncytial virus (RSV) (51), 300,000-650,000 deaths per year caused by influenza-A and-B (52), and ~15 million deaths in two years since the emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 2019 (53). Unlike cell therapy for CF where cell engraftment is key, the primary goal of cell therapy for severe viral infection would be to promote lung repair.…”